AR121002A2 - Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica - Google Patents
Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodiméricaInfo
- Publication number
- AR121002A2 AR121002A2 ARP210100032A ARP210100032A AR121002A2 AR 121002 A2 AR121002 A2 AR 121002A2 AR P210100032 A ARP210100032 A AR P210100032A AR P210100032 A ARP210100032 A AR P210100032A AR 121002 A2 AR121002 A2 AR 121002A2
- Authority
- AR
- Argentina
- Prior art keywords
- domain
- proteins
- detection
- isolation
- high levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Las proteínas de captura de la superficie celular recombinantes y las moléculas de detección que son útiles para aislar y detectar las células que producen una proteína secretada de interés (POI) tal como ciertas proteínas heterodiméricas que tienen un dominio CH3 de inmunoglobulina y/o un dominio CH3 sustituido. También se proporcionan proteínas de captura de la superficie celular recombinantes y las moléculas de detección que aíslan y detectan anticuerpos biespecíficos. La presente también proporciona proteínas de unión a antígenos recombinantes que son capaces de reconocer y unirse a las proteínas de interés que contienen un dominio CH3 con o sin sustituciones de aminoácidos en H95 e Y96 (IMGT). Reivindicación 1: Una proteína de unión a antígeno recombinante, caracterizada porque se une a un dominio de IgG1-Fc humano, un dominio de IgG2-Fc humano, o un dominio de IgG4-Fc humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726040P | 2012-11-14 | 2012-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121002A2 true AR121002A2 (es) | 2022-04-06 |
Family
ID=49679651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104196A AR093491A1 (es) | 2012-11-14 | 2013-11-14 | Proteinas de captura de superficie celular recombinantes |
| ARP210100032A AR121002A2 (es) | 2012-11-14 | 2021-01-07 | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104196A AR093491A1 (es) | 2012-11-14 | 2013-11-14 | Proteinas de captura de superficie celular recombinantes |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9758592B2 (es) |
| EP (2) | EP2949667B1 (es) |
| JP (2) | JP6668074B2 (es) |
| KR (4) | KR20150084028A (es) |
| CN (2) | CN109485728A (es) |
| AR (2) | AR093491A1 (es) |
| AU (3) | AU2013344769B2 (es) |
| BR (1) | BR112015010758A2 (es) |
| CA (2) | CA3204343A1 (es) |
| DK (2) | DK2949667T3 (es) |
| EA (2) | EA202190266A1 (es) |
| ES (2) | ES2817373T3 (es) |
| HK (2) | HK1211036A1 (es) |
| IL (3) | IL285015B1 (es) |
| MX (2) | MX2015006112A (es) |
| PL (2) | PL2920208T3 (es) |
| SG (2) | SG10201804124XA (es) |
| TW (4) | TWI675044B (es) |
| WO (1) | WO2014078475A2 (es) |
| ZA (1) | ZA201502538B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP2663579B1 (en) | 2011-01-14 | 2017-04-26 | The Regents of the University of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| WO2016079739A2 (en) * | 2014-11-20 | 2016-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
| PL3294775T3 (pl) * | 2015-05-12 | 2021-12-13 | Regeneron Pharmaceuticals, Inc. | Oznaczanie czystości białka multimerycznego |
| IL258009B2 (en) * | 2015-09-15 | 2024-03-01 | Univ Texas | Antibodies that bind receptors on T cells (TCR) and their use |
| KR20180134894A (ko) | 2016-04-20 | 2018-12-19 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
| CA3015389A1 (en) | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
| EP3601558A4 (en) | 2017-03-24 | 2021-01-06 | Lankenau Institute for Medical Research | METHODS AND COMPOSITIONS FOR CAPTURE OF INDUCTIBLE EXTRACELLULAR MEMBRANE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS |
| CN107177613A (zh) * | 2017-07-18 | 2017-09-19 | 哈尔滨紫霞生物科技有限公司 | 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法 |
| US20200369784A1 (en) * | 2017-12-07 | 2020-11-26 | Chugai Seiyaku Kabushiki Kaisha | Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample |
| EP3856910A4 (en) * | 2018-09-24 | 2022-09-28 | Merck Sharp & Dohme Corp. | EXPRESSION VECTORS FOR EUKARYOT EXPRESSION SYSTEMS |
| US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151350A (en) * | 1982-10-27 | 1992-09-29 | Repligen Corporation | Cloned genes encoding recombinant protein a |
| US5635354A (en) | 1991-01-09 | 1997-06-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
| AU679949B2 (en) | 1992-10-21 | 1997-07-17 | Stefan Miltenyi | Direct selection of cells by secretion product |
| US6482655B1 (en) | 1993-07-23 | 2002-11-19 | University Of Utah Research Foundation | Immunoassay procedure utilizing fluorogenic tracer antigens |
| US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6232066B1 (en) | 1997-12-19 | 2001-05-15 | Neogen, Inc. | High throughput assay system |
| JP4601166B2 (ja) | 1998-05-11 | 2010-12-22 | ミルテニィ バイオテック ゲーエムベーハー | 抗原特異的ｔ細胞の直接的選択方法 |
| EP1081224B1 (en) | 1998-05-20 | 2006-06-07 | Chugai Seiyaku Kabushiki Kaisha | Novel method for cloning a gene |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| DE19900635A1 (de) | 1999-01-11 | 2000-07-13 | Deutsches Krebsforsch | Selektion von monoklonalen Antikörpern |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20140072980A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US20140072979A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| ATE325865T1 (de) | 2001-01-16 | 2006-06-15 | Regeneron Pharma | Isolierung von sezernierte proteine exprimierenden zellen |
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
| CA2462113C (en) | 2001-10-01 | 2013-01-29 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
| EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| MY147651A (en) * | 2007-07-31 | 2012-12-31 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP3916011A1 (en) * | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| CN102770537A (zh) | 2009-12-25 | 2012-11-07 | 中外制药株式会社 | 用于纯化多肽多聚体的多肽的修饰方法 |
| TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
-
2013
- 2013-11-13 TW TW102141304A patent/TWI675044B/zh active
- 2013-11-13 TW TW110138498A patent/TW202206465A/zh unknown
- 2013-11-13 TW TW112140518A patent/TW202423993A/zh unknown
- 2013-11-13 TW TW107128129A patent/TWI745610B/zh active
- 2013-11-14 WO PCT/US2013/069993 patent/WO2014078475A2/en active Application Filing
- 2013-11-14 KR KR1020157014594A patent/KR20150084028A/ko active Application Filing
- 2013-11-14 CN CN201811342204.8A patent/CN109485728A/zh active Pending
- 2013-11-14 CA CA3204343A patent/CA3204343A1/en active Pending
- 2013-11-14 AR ARP130104196A patent/AR093491A1/es active IP Right Grant
- 2013-11-14 PL PL13798483T patent/PL2920208T3/pl unknown
- 2013-11-14 CA CA2889541A patent/CA2889541C/en active Active
- 2013-11-14 PL PL15172149T patent/PL2949667T3/pl unknown
- 2013-11-14 SG SG10201804124XA patent/SG10201804124XA/en unknown
- 2013-11-14 JP JP2015542760A patent/JP6668074B2/ja active Active
- 2013-11-14 DK DK15172149.5T patent/DK2949667T3/da active
- 2013-11-14 KR KR1020237026105A patent/KR20230119245A/ko not_active Application Discontinuation
- 2013-11-14 EA EA202190266A patent/EA202190266A1/ru unknown
- 2013-11-14 CN CN201380059198.4A patent/CN104797598B/zh active Active
- 2013-11-14 DK DK13798483.7T patent/DK2920208T3/da active
- 2013-11-14 AU AU2013344769A patent/AU2013344769B2/en active Active
- 2013-11-14 IL IL285015A patent/IL285015B1/en unknown
- 2013-11-14 US US14/079,686 patent/US9758592B2/en active Active
- 2013-11-14 EP EP15172149.5A patent/EP2949667B1/en active Active
- 2013-11-14 KR KR1020217003226A patent/KR20210014766A/ko not_active IP Right Cessation
- 2013-11-14 EA EA201590928A patent/EA037546B1/ru unknown
- 2013-11-14 ES ES13798483T patent/ES2817373T3/es active Active
- 2013-11-14 BR BR112015010758A patent/BR112015010758A2/pt not_active Application Discontinuation
- 2013-11-14 ES ES15172149T patent/ES2805526T3/es active Active
- 2013-11-14 KR KR1020227004696A patent/KR102563030B1/ko active IP Right Grant
- 2013-11-14 EP EP13798483.7A patent/EP2920208B1/en active Active
- 2013-11-14 MX MX2015006112A patent/MX2015006112A/es active IP Right Grant
- 2013-11-14 SG SG11201502629TA patent/SG11201502629TA/en unknown
-
2015
- 2015-04-12 IL IL238176A patent/IL238176B/en active IP Right Grant
- 2015-04-15 ZA ZA2015/02538A patent/ZA201502538B/en unknown
- 2015-05-14 MX MX2019015887A patent/MX2019015887A/es unknown
- 2015-11-26 HK HK15111643.1A patent/HK1211036A1/xx unknown
-
2016
- 2016-03-07 HK HK16102584.0A patent/HK1214612A1/zh unknown
-
2017
- 2017-09-11 US US15/700,404 patent/US20180118852A1/en not_active Abandoned
-
2018
- 2018-09-20 JP JP2018175921A patent/JP6856593B2/ja active Active
- 2018-10-23 AU AU2018253474A patent/AU2018253474B2/en active Active
-
2020
- 2020-06-10 IL IL275270A patent/IL275270B/en unknown
- 2020-09-18 US US17/025,656 patent/US20210009714A1/en active Pending
-
2021
- 2021-01-07 AR ARP210100032A patent/AR121002A2/es unknown
- 2021-04-19 AU AU2021202371A patent/AU2021202371B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121002A2 (es) | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica | |
| PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
| DOP2014000029A (es) | Proteínas y péptidos modificados. | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| EA201791057A1 (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf | |
| MX2020001227A (es) | Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. | |
| CO6480976A2 (es) | Polipeptidos y metodo de tratamiento | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| AR093984A1 (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano | |
| EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| GT201300149A (es) | Proteinas de union al tnf-a | |
| BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
| MY162752A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| EA201792376A3 (ru) | Молекулы анти-gcc антитела и соответствующие композиции и способы | |
| CO6400231A2 (es) | Proteínas de unión a il-1 | |
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
| MX353464B (es) | Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles. | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
| WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
| EA201792661A1 (ru) | Способ получения антител против т-клеточного рецептора | |
| EA201100741A1 (ru) | Антитела к модифицированным пептидам ифр-1/е человека |